Inventaire - your friends and communities are your best library

Non-peptide arginine-vasopressin antagonists: the vaptans

author

Gilbert Vassart

published in: The Lancet

date of publication: 2008-05-01

language: English

main subject: AVP

Cites articles 70

Date

Title

Authors

2007-02-01

Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists

Daniel Batlle
2007-01-17

Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree.
2007-07-26

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
2007-03-25

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

Mihai Gheorghiade, Liliana Grinfeld, Faiez Zannad, Karl Swedberg
2007-03-25

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

Mihai Gheorghiade, Liliana Grinfeld, Faiez Zannad, Karl Swedberg, Aldo P. Maggioni
2007-05-18

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction

James E Udelson
2006-08-01

Vasopressin antagonists.
2006-05-01

Vaptans and the treatment of water-retaining disorders
2006-06

Vasopressin receptor antagonists
2006-07-11

Vasopressin antagonists: role in the management of hyponatremia
2006-01-01

Conivaptan: a selective vasopressin antagonist for the treatment of heart failure

Ernst Schwarz
2006-03-07

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
2006-11-14

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

Mihai Gheorghiade, Robert William Schrier
2006-03-29

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients

Robert William Schrier
2006-10-11

Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist

Djillali Annane
2006-01-01

Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis
2006-02-01

Neurological impact of vasopressin dysregulation and hyponatremia
2006-01-01

Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits
2005-01-01

The central vasopressinergic system: examining the opportunities for psychiatric drug development

Robert H. Ring
2005-08-10

Molecular biology of hereditary diabetes insipidus

Daniel-G. Bichet
2005-05-01

Nephrogenic syndrome of inappropriate antidiuresis

B J Feldman
2005-10-18

Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor
2005-02-01

The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor
2005-01-01

Pharmacologic management of Cushing syndrome : new targets for therapy

Marco Boscaro, Francesco Fallo
2005-10-05

Neurohormonal inhibition in heart failure: insights from recent clinical trials

Mihai Gheorghiade
2005-11-01

Vasopressin antagonists in polycystic kidney disease
2005-02-23

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
2005-10-05

Hyponatremia in patients with heart failure.

Mihai Gheorghiade, James E Udelson
2005-05-02

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

Mihai Gheorghiade, Robert Califf, Christopher M O'Connor, Gary Felker, Ileana L Piña, Kirkwood F Adams, Wendy Gattis Stough, Jeffrey D Leimberger, OPTIME-CHF Investigators
2005-11-30

Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.

Michel Bouvier
2005-01-01

Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure
2004-04-28

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

Mihai Gheorghiade, Christopher M O'Connor

Article - wd:Q34777664

Welcome to Inventaire

the library of your friends and communities

learn more